CompletedNCT01029769
Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
Medication studyAges 18–65Germany
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Munich, GermanySee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateDecember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 350
- Sponsor
- Technical University of Munich
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Germany
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01029769
- Official title
Show the full official title
The Switch Study - Efficacy of Early Antipsychotic Switch Versus Maintenance in Patients With Schizophrenia Poorly Responding to Two Weeks of Antipsychotic Treatment
Recruitment & locations
CompletedMunich
Questions about this study
Who is behind this study?
The study sponsor is Technical University of Munich, a university.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine or amisulpride.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2008-002247-16
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
France, United Kingdom, Belgium, + 10 others
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study evaluated the safety of EVP-6124 for people with schizophrenia.
CompletedEUCTR 2004-000751-42
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...
Germany